Modified recombinant factor viii and von willebrand factor and methods of use

a technology of recombinant factor and modified recombinant factor, which is applied in the field of modified recombinant factor viii and von willebrand factor and methods of use, can solve the problems of limiting the molecular field as to the clearance mechanism of factor viii, and affecting the survival of hemophilic patients, so as to increase the survival of factor viii, inhibit the clearance receptor of coagulation protein,

Inactive Publication Date: 2012-12-20
BAXTER INT INC +1
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This constitutes a heavy load on the life of hemophilic patients, in particular, if the venous access has become difficult due to local citratization following frequent needle punctures for intravenous infusions.
However, the design of such agents has so far been impeded by not knowing the Factor VIII clearance mechanism, the cell receptors involved in this process, and the molecular sites involved in the Factor VIII receptor interaction.
There is limited knowledge in the molecular field as to the clearance mechanism of Factor VIII.
Nevertheless, its half-life remains undesirably short.
LRP secretion may be complicated by LRP interacting with multiple ligands.
This led to the discovery that specific mutations in this region weaken the interaction between the proteins.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified recombinant factor viii and von willebrand factor and methods of use
  • Modified recombinant factor viii and von willebrand factor and methods of use
  • Modified recombinant factor viii and von willebrand factor and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0147]It has been shown that LRP1 contributes to the regulation of FVIII plasma levels. LRP1 is a cellular receptor that is able to bind and transport FVIII to intracellular degradation pathways. The present example, demonstrates that PEGylation or polysialylation of FVIII disrupts in vitro binding to LRP1.

[0148]Components: Purified recombinant wild-type FVIII (batch MOQ-Hepes-08E; 2.28 mg / ml; 12117 IU / ml); PEGylated FVIII (batch hydrolysable PEG-rFVIII ORHLUFB07001PHR; 1.76 mg / ml; 2498 IU / ml); polysialylated FVIII (batch PSA-rFVIII-11.0 KD NHS; 0.613 mg / ml; 268 IU / ml). Purified LRP1 was obtained from Biomac (Leipzig; Cat no. #04-03).

[0149]Experimental design: Binding of FVIII or its derivatives to LRP1 was assessed using surface plasmon resonance (SPR) analysis using Biacore2000 equipment. Specifications: LRP1 was immobilized on a standard CM5-biosensorchip (Biacore). The flow rate was set at 20 μl / min to avoid potential rebinding due to mass-transfer limitations. Samples were run ...

example 2

[0151]Binding of FVIII to LRP1 is inhibited in the presence of VWF, because LRP1 interaction sites within the FVIII light chain are inaccessible when FVIII is bound to VWF. The present example demonstrates that PEGylation or polysialylation of vWF does not interfere with the vWF-mediated inhibition of LRP1 binding by FVIII.

[0152]Components: Purified recombinant wild-type FVIII (batch MOQ-Hepes-08E; 2.28 mg / ml; 12117 IU / ml); recombinant-wt-vWF (batch ORWSEC06006F1HL; 0.464 mg / ml; 72.1 IU Ag / ml; 20.6 IU RCo / ml), stable PEG-vWF (batch NTT-VWF-600-S2 I; 1.021 mg / ml; 61.4 IU Ag / ml; 41.9 IU RCo / ml); and stable PSA-vWF (batch PSA-RVWF-19.3 KD CAO batch2 (Jun. 10, 2006); 0.0087 mg / ml; 11.3 IU Ag / ml; 0.2 IU RCo / ml).

[0153]Wild-type recombinant FVIII (40 nM) was pre-incubated with various concentrations of vWF (0-400 nM for wt-vWF and PEG-vWF and 0-200 nM for PSA-vWF). Concentrations of vWF were based on protein concentrations and a molecular weight of 250 kDa per vWF monomer. Again, since the...

example 3

[0159]The relationship between the half-life survival rate of FVIII in the presence and absence of VWF was studied in patients with Haemophilia A and Von Willebrand Disease type 3. Haemophilia A patients have a deficiency in FVIII levels, but typically display normal VWF expression. Conversely, patients with Von Willebrand Disease (VWD) type 3 are homozygous for deficient VWF, but show normal FVIII expression. However, despite the normal expression of FVIII in patients with Von Willebrand Disease type 3, plasma levels of the clotting factor are greatly reduced, presumably due to a lack of protection normally provided by stable binding of VWF to FVIII. Thus, it is predicted that administration of a FVIII concentrate to Haemophilia A patients will result in a longer half life of the clotting factor than will administration to patients with Von Willebrand Disease type 3.

[0160]The hypothesis presented above was tested by determining the survival rate of administered FVIII in Haemophilia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 12 / 267,491, filed Nov. 7, 2008, which claims priority to U.S. Application Ser. No. 60 / 986,975, filed Nov. 9, 2007, herein incorporated by reference in its entirety.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]NOT APPLICABLEREFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK[0003]NOT APPLICABLEBACKGROUND OF THE INVENTION[0004]Hemostasis involves the interaction of various hemostatic reaction routes finally leading to thrombus formation. Thrombi are deposits of blood components on the surface of the vascular wall that mainly consist of aggregated blood platelets and insoluble cross-linked fibrin. Fibrin formation is the result of the restricted proteolysis of fibrinogen by thrombin, a coagulation enzyme. Thrombin is the end product of the coagulation cascade, a succes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/36A61P7/04
CPCA61K38/37C07K14/755C08G65/329C08H1/00C08L63/00C08L2203/02A61K47/60A61K47/61A61P7/00A61P7/04A61K47/549
Inventor SCHWARZ, HANS-PETERTURECEK, PETER
Owner BAXTER INT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap